Trial Profile
VRC 207: A Phase I, Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC EBOADC069-00-VP, in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 3390107A (Primary) ; VRC-EBOADC069-00-VP (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- 06 Apr 2017 Status changed from active, no longer recruiting to completed.
- 07 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 07 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.